These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21814034)

  • 1. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.
    Iwaizumi M; Tseng-Rogenski S; Carethers JM
    Cancer Biol Ther; 2011 Oct; 12(8):756-64. PubMed ID: 21814034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity.
    Iwaizumi M; Tseng-Rogenski S; Carethers JM
    Mutat Res; 2013; 747-748():19-27. PubMed ID: 23643670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation rate but not mismatch repair affects the long-term response of colon carcinoma cells to 5FU treatment.
    Choudhary B; Hanski ML; Zeitz M; Hanski C
    Cancer Lett; 2012 Jul; 320(1):56-64. PubMed ID: 22266192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.
    Suzuki S; Iwaizumi M; Tseng-Rogenski S; Hamaya Y; Miyajima H; Kanaoka S; Sugimoto K; Carethers JM
    Cancer Biol Ther; 2016 Jul; 17(7):760-8. PubMed ID: 27115207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.
    Meyers M; Wagner MW; Hwang HS; Kinsella TJ; Boothman DA
    Cancer Res; 2001 Jul; 61(13):5193-201. PubMed ID: 11431359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    Arnold CN; Goel A; Boland CR
    Int J Cancer; 2003 Aug; 106(1):66-73. PubMed ID: 12794758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
    Chung H; Chaudhry J; Lopez CG; Carethers JM
    Cancer Biol Ther; 2010 Dec; 10(11):1147-56. PubMed ID: 20930505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
    Adamsen BL; Kravik KL; De Angelis PM
    Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
    Oliver JA; Ortiz R; Jimenez-Luna C; Cabeza L; Perazzoli G; Caba O; Mesas C; Melguizo C; Prados J
    J Biosci; 2020; 45():. PubMed ID: 33097678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
    de Castro E Gloria H; Jesuíno Nogueira L; Bencke Grudzinski P; da Costa Ghignatti PV; Guecheva TN; Motta Leguisamo N; Saffi J
    BMC Cancer; 2021 Apr; 21(1):448. PubMed ID: 33888065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
    Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
    Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells.
    Fujita H; Kato J; Horii J; Harada K; Hiraoka S; Shiraha H; Sakaguchi K; Shiratori Y
    Oncol Rep; 2007 Nov; 18(5):1129-37. PubMed ID: 17914563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells.
    Qi Y; Schoene NW; Lartey FM; Cheng WH
    J Biol Chem; 2010 Oct; 285(43):33010-33017. PubMed ID: 20709753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA mismatch repair initiates 6-thioguanine--induced autophagy through p53 activation in human tumor cells.
    Zeng X; Yan T; Schupp JE; Seo Y; Kinsella TJ
    Clin Cancer Res; 2007 Feb; 13(4):1315-21. PubMed ID: 17317843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
    Park JM; Huang S; Tougeron D; Sinicrope FA
    PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both hMutSα and hMutSß DNA mismatch repair complexes participate in 5-fluorouracil cytotoxicity.
    Tajima A; Iwaizumi M; Tseng-Rogenski S; Cabrera BL; Carethers JM
    PLoS One; 2011; 6(12):e28117. PubMed ID: 22164234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer.
    Ma J; Zhang Y; Shen H; Kapesa L; Liu W; Zeng M; Zeng S
    Tumour Biol; 2015 Dec; 36(12):9599-609. PubMed ID: 26142736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.